Saudi Value-based Healthcare: The Bold Shift That Finally Aligns Payers, Providers, and Outcomes

Saudi value-based healthcare is becoming more practical. The focus is shifting from paying for activity to paying for outcomes people can see and report. This matters because Saudi Arabia has both public and private care, and payers and providers must work together to make outcomes measurement routine, not a special project.

Some signals are clear. The Ministry of Health (MOH) has historically been the primary provider and payer and accounts for around 60% of healthcare expenditure. At the same time, the cooperative health insurance market has grown to more than USD 10 billion, shaped by employer-sponsored group policies and expanded dependent coverage. This mix makes alignment difficult, but it also creates room to test payment and reporting models across different payer types.

A payer-led implementation is now taking shape. Tawuniya Insurance partnered with The Clinician to deploy a digital health platform that embeds ICHOM standards and the OECD Patient-Reported Indicator Survey (PaRIS) initiative across the local health system. The announcement describes this as the first payer-led dual implementation of the ICHOM and PaRIS frameworks in the Kingdom. The work is also described as aligned with emerging priorities around interoperability and outcomes reporting across NPHIES, CHI, and CNHI.

One concrete capacity metric is the planned expansion of the delivery network tied to this work. Meena Health, Tawuniya’s fully-owned primary care network, currently operates 5 clinics and has a roadmap to expand to more than 50 centers by 2027. That type of growth matters for value-based care because outcomes collection must fit day-to-day clinical practice as scale increases.

From Measurement to Payment: Linking PROMs and Costs

Outcomes measurement becomes more useful when it connects to cost and payment design. A Tawuniya study examined the real-world implementation of the ICHOM Low Back Pain Set within an insured population. It analyzed longitudinal patient-reported outcome measures (PROMs) and episode-of-care costs for 97 patients treated between August 2023 and March 2025, with follow-up at 1, 3, and 6 months. The results showed clinically meaningful improvements over time, alongside notable variation in treatment costs.

The same study highlights why payer-provider alignment is not only technical. It reports that patient characteristics such as BMI, education level, gender, and comorbidities are associated with outcomes. That supports the need for risk adjustment and sustained measurement when standardized sets are used in practice. It also shows how linking outcomes with cost data at payer level can inform benchmarking, payment design, and system-level decisions.

Policy tools are also changing around the care journey. Vision 2030 is linked to new health technology assessment (HTA), pricing, and reimbursement reforms that aim for value-based access to health technologies. HTA has been formalised, and the Centre of Health Technology Assessment (CHTA) is responsible for the economic evaluation of pharmaceutical products to support reimbursement decisions across public and private sectors. Managed Entry Agreements (MEAs), both financial- and outcomes-based, are described as increasingly used to support market uptake strategies.